172 filings
Page 7 of 9
8-K
1049o1e0mta
8 Mar 17
Trevena Reports Full Year 2016 Earnings
12:00am
8-K
n4yiel 14
3 Mar 17
Departure of Directors or Certain Officers
12:00am
8-K
hcai08e1s5op340
21 Feb 17
Trevena Announces Positive Top-line Results from Two Phase 3 Pivotal Efficacy Studies of Intravenous Oliceridine in Moderate-to-Severe Acute Pain
12:00am
8-K
9kbaw6c3hs wwdad
6 Jan 17
Departure of Directors or Certain Officers
12:00am
8-K
auod hg2c0p2m
4 Jan 17
Entry into a Material Definitive Agreement
12:00am
8-K
3pfrwphvj 0b
4 Jan 17
Regulation FD Disclosure
12:00am
8-K
6yorxczcgnevkh2
19 Dec 16
Departure of Directors or Certain Officers
12:00am
8-K
3l551nbce3
14 Dec 16
Entry into a Material Definitive Agreement
12:00am
8-K
l26x48nlba
3 Nov 16
Trevena Reports Third Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
7k0wj
4 Aug 16
Trevena Reports Second Quarter 2016 Financial Results and Provides Corporate Update
12:00am
8-K
batky8l5
19 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
sxwe2ne7
16 May 16
Trevena Reports TRV027 Did Not Achieve Primary or Secondary Endpoints in BLAST-AHF Phase 2b Trial in Acute Heart Failure
12:00am
8-K
dozq7db8u1v
5 May 16
Trevena Reports First Quarter 2016 Financial Results
12:00am
8-K
mvvuaitmvdgp xz
2 May 16
Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine
12:00am
8-K
xeq yeagl0gr5
9 Mar 16
Trevena Reports Full Year 2015 Financial Results
12:00am
8-K
1uev3
9 Mar 16
Departure of Directors or Certain Officers
12:00am
8-K
wvhv1 5c9klivzy
23 Feb 16
Other Events
12:00am
8-K
2pz8bq
23 Dec 15
Entry into a Material Definitive Agreement
12:00am
8-K
srphi3vu9k5hcnl s5
14 Dec 15
Entry into a Material Definitive Agreement
12:00am
8-K
3hrg0i
11 Dec 15
Entry into a Material Definitive Agreement
12:00am